Previously, HER2-low tumors were not considered suitable for treatment with HER2-directed agents.[30] Recent studies[31,32] have shown that mutations in the PI3K/AKT/mTOR pathway play a significant role in trastuzumab resistance in HER2-low BC patients. Here, ERBB2 is linked to breast cancer.